Reivindicaciones
1. A compound of formula (I) <img class="EMIRef" id="463427445-ib0020" /> wherein R is selected from the group consisting of: - (C<1> -C<6> )alkyl optionally substituted by one, two, or three halogen atoms selected from fluorine, chlorine and bromine; (C<3> -C<6> )cycloalkyl; (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkoxyl; cyano and nitro; or two groups can form together a group -O(CH<2> )<m> O-, or -(CH<2> )p-, or -CH=CH-CH=CH-; or - phenyl optionally substituted by one, two or three groups independently selected form fluorine; chlorine; bromine; (C<1> -C<6> )alkyl optionally substituted by one, two, or three halogen atoms selected from fluorine, chlorine, and bromine; (C<3> -C<6> )cycloalkyl; (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkoxyl; cyano and nitro; or two groups can form together a group -O(CH<2> )<m> O-, -(CH<2> )p-, or -CH=CH-CH=CH-; and/or - an heteroaryl group selected from 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 2-pyrrolyl, 3-pyrrolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,2,5-thiadiazol-3-yl, 1,3,4-thiadiazol-2-yl, 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl and 5-tetrazolyl, being the heteroaryl group optionally substituted by one, two or three groups independently selected from fluorine, chlorine, and bromine, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, (C<1> -C<6> )alkoxyl, (C<3> -C<6> )cycloalkoxyl, cyano and nitro; R<1> and R<2> are selected from the group consisting of hydrogen, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, and phenyl, optionally substituted by one, two or three groups independently selected from fluorine, chlorine, and bromine, (C<1> -C<6> )alkyl, (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano, nitro, and carboxilate or two groups can form together a group -O(CH<2> )<q> O-, -(CH<2> )<r> -, or -CH=CH-CH=CH-; R<3> , R<4> and R<5> are selected from the group consisting of hydrogen (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, and phenyl, optionally substituted by one, two or three groups independently selected from fluorine, chlorine, and bromine, (C<1> -C<6> )alkyl, (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano, nitro, and carboxylate or two groups can form together a group -O(CH<2> )<q> O-, -(CH<2> )<r> -, or -CH=CH-CH=CH-; R<6> is selected from the group consisting of hydrogen, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, and phenyl, optionally substituted by one, two or three groups independently selected form fluorine, chlorine, bromine, (C<1> -C<6> )alkyl, (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano and nitro; R<7> is selected from the group consisting of hydrogen, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, acetyl or phenyl, optionally substituted by one, two or three groups independently selected from fluorine, chlorine and bromine, (C<1> -C<6> )alkyl, (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano, nitro or two groups can form together a group -(CH<2> )<s> -, or -CH=CH-CH=CH- R<8> is selected from the group consisting of hydrogen, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, acetyl or phenyl, optionally substituted by one, two or three groups independently selected from fluorine, chlorine, and bromine, (C<1> -C<6> )alkyl, (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl; cyano and nitro or two groups can form together a group -(CH<2> )<s> -, or -CH=CH-CH=CH- or R<7> = R<8> of formula =C=S X is selected from an oxygen atom, a nitrogen atom or a sulphur atom, -SO- or SO<2> n is an integer selected from 0, 1, 2, 3, 4 or 5; their salts, prodrugs, or solvates. 2. A compound according to claim 1, wherein R is selected from the group consisting of phenyl optionally substituted by one or two groups independently selected from fluorine; chlorine; (C<1> -C<6> )alkyl optionally substituted by one, two, or three halogen atoms selected from fluorine, chlorine, and bromine; (C<1> -C<6> )alkoxyl and nitro; or one heterocycle optionally substituted by one or two groups independently selected from fluorine; chlorine; (C<1> -C<6> )alkyl; alkoxyl and nito, R<1> is hydrogen; R<2> is hydrogen; R<3> is hydrogen; R<4> is hydrogen; R<5> is hydrogen; R<6> is hydrogen; R<7> is acyl (C2) R<8> is hydrogen; and n is an integer selected from 0, 1 and 2; and their salts, prodrugs or solvates, preferably, their pharmaceutically acceptable salts. 3. A compound according to claim 1, wherein R is phenyl optionally substituted by a group selected from fluorine; (C<1> -C<6> )alkyl optionally substituted by one, two, or three halogen atoms selected from fluorine, chlorine and bromine; (C<1> -C<6> )alkoxyl and nitro; R<7> is acyl; R<8> is hydrogen; and n is 1; and their salts, prodrugs or solvates, preferably, their pharmaceutically acceptable salts. 4. A compound according to claim 1, wherein R is phenyl optionally substituted by a group selected from fluorine; (C<1> -C<6> )alkyl optionally substituted by one, two or three halogen atoms selected from fluorine, chlorine or bromine; (C<1> -C<6> )alkoxyl and nitro; R<7> = R<8> is =C=S; and n is 1; and their salts, prodrugs or solvates, preferably, their pharmaceutically acceptable salts. 5. A compound according to claim 3, selected from: • 3-(2-acetamidoethyl)-1H -indol-5-yl cinnamate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(3-methoxyphenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-methoxyphenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(2-methoxyphenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-chlorophenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-bromophenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-fluorophenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(3-(trifluoromethyl)phenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-(trifluoromethyl)phenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(2-(trifluoromethyl)phenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-methylphenyl)acrylate • 3-(2-acetamidoethyl)-1H indol-5-yl (E )-3-(3,4-dichlorophenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-nitrophenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-2-butenoate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-hydroxyphenyl)acrylate • 3-(2-acetamidoethyl)-1H -indol-5-yl (E )-3-(4-hydroxy-3-methoxyphenyl)acrylate 6. A process for the preparation of a compound of formula (I) <img class="EMIRef" id="463427445-ib0021" /> wherein R is selected from the group consisting of: - (C<1> -C<6> )alkyl optionally substituted by one, two, or three halogen atoms selected from fluorine, chlorine, and bromine; (C<3> -C<6> )cycloalkyl; (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkoxyl; cyano and nitro; or two groups can form together a group -O(CH<2> )<m> O-, or -(CH<2> )p-, or -CH=CH-CH=CH-; or - phenyl optionally substituted by one, two or three groups independently selected form fluorine; chlorine; bromine; (C<1> -C<6> )alkyl optionally substituted by one, two, or three halogen atoms selected from fluorine, chlorine, and bromine; (C<3> -C<6> )cycloalkyl; (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkoxyl; cyano and nitro; or two groups can form together a group -O(CH<2> )<m> O-, -(CH<2> )p-, or -CH=CH-CH=CH-; and/or - an heteroaryl group selected from 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 2-pyrrolyl, 3-pyrrolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,2,5-thiadiazol-3-yl, 1,3,4-thiadiazol-2-yl, 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl, and 5-tetrazolyl, being the heteroaryl group optionally substituted by one, two or three groups independently selected from fluorine, chlorine, and bromine, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, (C<1> -C<6> )alkoxyl, (C<3> -C<6> )cycloalkoxyl, cyano and nitro; R<1> and R<2> are selected from the group consisting of hydrogen, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, and phenyl, optionally substituted by one, two, or three groups independently selected from fluorine, chlorine, and bromine, (C<1> -C<6> )alkyl, (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano, nitro and carboxilate or two groups can form together a group -O(CH<2> )<q> O-, -(CH<2> )<r> -, or -CH=CH-CH=CH-; R<3> , R<4> and R<5> are selected from the group consisting of hydrogen (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, and phenyl, optionally substituted by one, two or three groups independently selected from fluorine, chlorine and bromine, (C<1> -C<6> )alkyl,(C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano, nitro and carboxilate or two groups can form together a group -O(CH<2> )<q> O-, -(CH<2> )<r> -, or -CH=CH-CH=CH-; R<6> is selected from the group consisting of hydrogen, (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl and phenyl, optionally substituted by one, two or three groups independently selected form fluorine, chlorine, bromine, (C<1> -C<6> )alkyl, (C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano and nitro; R<7> is selected from the group consisting of hydrogen (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, acetyl or phenyl, optionally substituted by one, two or three groups independently selected from fluorine, chlorine and bromine, (C<1> -C<6> )alkyl,(C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano, nitro or two groups can form together a group -(CH<2> )<s> -, or -CH=CH-CH=CH-; R<8> is selected from the group consisting of hydrogen (C<1> -C<6> )alkyl, (C<3> -C<6> )cycloalkyl, acetyl or phenyl, optionally substituted by one, two or three groups independently selected from fluorine, chlorine and bromine, (C<1> -C<6> )alkyl,(C<1> -C<6> )alkoxyl; (C<3> -C<6> )cycloalkyl, (C<3> -C<6> )cycloalkoxyl, cyano and nitro or two groups can form together a group -(CH<2> )<s> -, or -CH=CH-CH=CH-; or R<7> = R<8> of formula =C=S; X is selected from an oxygen atom, a nitrogen atom or an sulphur atom, -SO- or SO<2> n is an integer selected from 0, 1, 2, 3, 4 or 5; and their salts, prodrugs or solvates, that comprises the reaction of an acid of formula (II): <img class="EMIRef" id="463427445-ib0022" /> where R, R<1> and R<2> have the meaning previously indicated; with a compound of formula (III): <img class="EMIRef" id="463427445-ib0023" /> where, R<3> , R<4> , R<5> , R<6> , R<7> , R<8> and n have the meaning previously indicated. 7. The process according to claim 6, wherein the reaction between the compound of formula (II) and the compound of formula (III) is performed in the presence of a catalyst selected from HATU, DCC, or EDCI, in a solvent selected from dichloromethane, 1,2-dichloroethane, chloroform and mixtures thereof 8. A pharmaceutical composition of a compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and a pharmaceutically acceptable excipient. 9. Use of a compound of formula (I) according to any one of the claims 1 to 5, or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the preparation of a pharmaceutical composition with Nrf2 induction effect and/or antioxidant and/or neuroprotectant and/or immunomodulator. 10. Use of a compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, in the preparation of a pharmaceutical composition for the prevention or the treatment of a central and/or peripheral neurodegenerative disease or of a cerebro-isquemic disease (ictus). 11. Use according to claim 9, wherein the neurodegenerative disease is Alzheimer's disease. 12. Use according to claim 9, wherein the neurodegenerative disease is Parkinson's disease. 13. Use according to claim 9, wherein the neurodegenerative disease is Huntington's disease. 14. Use according to claim 9, wherein the neurodegenerative disease is multiple sclerosis. 15. Use according to claim 9, wherein the neurodegenerative disease is cerebral ictus. 16. Use according to claim 9, wherein the neurodegenerative disease is amyotrophic lateral sclerosis. 17. Use according to any one of claims 8-16, wherein the compound of formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, is used for the manufacture of a medicine for oral, parental, subcutaneous, intramuscular, intravenous, or rectal administration. 18. Use according to any one of claims 8 to 18, wherein the compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, is administered in a daily dose between 0.1 and 100 mg/Kg of body weight. 19. Use according to claim 19, wherein the compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, is administered in a daily dose between 2 and 5 mg/Kg of body weight.
